Afatinib Dimaleate

DRUG8 trials

Sponsors

University of Chicago, Boehringer Ingelheim, Jonathan Riess, SWOG Cancer Research Network, University of Washington

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmBile Duct CarcinomaBladder CarcinomaBreast CarcinomaCarcinoma, Non-Small-Cell LungCervical CarcinomaColon Carcinoma

Phase 1

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

CompletedNCT02364609

Jonathan RiessRecurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer +1

Start: 2015-09-30End: 2020-05-01Updated: 2024-10-16

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

CompletedNCT02451553

University of WashingtonAdvanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm +4

Start: 2015-11-05End: 2022-04-16Updated: 2022-06-07

Phase 2

Afatinib in Advanced Refractory Urothelial Cancer

TerminatedNCT02122172

University of ChicagoDistal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer +6

Start: 2017-09-13End: 2024-04-04Updated: 2025-04-25

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Active, not recruitingNCT02438722

SWOG Cancer Research NetworkRecurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

Start: 2015-05-07End: 2026-12-31Updated: 2026-02-06

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active, not recruitingNCT02465060

National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49

Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Active, not recruitingNCT04439136

National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3

Start: 2015-08-12End: 2026-03-17Updated: 2025-09-05

Phase 4

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Shanghai Chest HospitalNRG1-fused Non-small Cell Lung Cancer

Start: 2021-06-01End: 2024-01-31Target: 15Updated: 2021-04-01

Unknown Phase

Long-term Observation PMS for Afatinib

CompletedNCT02131259

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2014-05-07End: 2016-12-28Updated: 2018-09-07

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

2025-10-09

Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.

Journal of Clinical Oncology2025-05-281 citations

Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers.

Journal of Clinical Oncology2025-01-271 citations

Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.

Journal of Clinical Oncology2024-06-011 citations

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Molecular Cancer Therapeutics2023-12-01

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

2023-11-0720 citations

The NCI-MATCH trial: lessons for precision oncology.

2023-06-15103 citations

Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology2023-06-012 citations

Discovery of gene fusions in driver-negative NCI-MATCH screening samples.

Journal of Clinical Oncology2023-06-011 citations

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine2023-04-14244 citations

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research2023-01-2055 citations

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology2022-10-2715 citations

Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease

Cancer Research2022-06-15

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

2022-06-077 citations

Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.

Journal of Clinical Oncology2022-06-013 citations

Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Journal of Clinical Oncology2022-06-01

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist2022-04-1445 citations

Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer

Cancer Research2022-02-151 citations

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.

2021-03-1921 citations

24 more papers not shown